BACKGROUND AND AIMS: The aim of this retrospective study is to assess the impact of calcineurin inhibitors on hepatitis C virus recurrence following liver transplantation. METHODS: A total of 396 patients underwent liver transplantation for hepatitis C virus-induced liver disease between 1991 and 2005 at a single center. We examined the pre- and post-operative characteristics of patients who received either cyclosporine (n = 126) or tacrolimus (n = 270) as maintenance immunosuppression. In addition, we compared the postoperative course, including patient, graft and hepatitis C virus recurrence-free survival between the two groups. RESULTS: There were no significant differences between the two groups in either post-operative hepatitis C virus-ribonucleic acid or histological fibrosis score (performed within 6 months after transplant per protocol). The graft and patient survivals did not differ between the two groups (logrank p = 0.34 and 0.15, respectively). Histologic hepatitis C virus recurrence-free survival, however, was significantly higher in the cyclosporine group than in the tacrolimus group (55.4 vs. 30.8% at 1 year, 18.6 vs. 10.3% at 3 years, 16.7 vs. 8.1% at 5 years, p < 0.001). CONCLUSIONS: Patients transplanted for hepatitis C virus and treated with cyclosporine versus tacrolimus may have a higher recurrence-free survival.
BACKGROUND AND AIMS: The aim of this retrospective study is to assess the impact of calcineurin inhibitors on hepatitis C virus recurrence following liver transplantation. METHODS: A total of 396 patients underwent liver transplantation for hepatitis C virus-induced liver disease between 1991 and 2005 at a single center. We examined the pre- and post-operative characteristics of patients who received either cyclosporine (n = 126) or tacrolimus (n = 270) as maintenance immunosuppression. In addition, we compared the postoperative course, including patient, graft and hepatitis C virus recurrence-free survival between the two groups. RESULTS: There were no significant differences between the two groups in either post-operative hepatitis C virus-ribonucleic acid or histological fibrosis score (performed within 6 months after transplant per protocol). The graft and patient survivals did not differ between the two groups (logrank p = 0.34 and 0.15, respectively). Histologic hepatitis C virus recurrence-free survival, however, was significantly higher in the cyclosporine group than in the tacrolimus group (55.4 vs. 30.8% at 1 year, 18.6 vs. 10.3% at 3 years, 16.7 vs. 8.1% at 5 years, p < 0.001). CONCLUSIONS:Patients transplanted for hepatitis C virus and treated with cyclosporine versus tacrolimus may have a higher recurrence-free survival.
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: M Berenguer; L Ferrell; J Watson; M Prieto; M Kim; M Rayón; J Córdoba; A Herola; N Ascher; J Mir; J Berenguer; T L Wright Journal: J Hepatol Date: 2000-04 Impact factor: 25.083
Authors: Paul Martin; Ronald W Busuttil; Robert M Goldstein; Jeffrey S Crippin; Goran B Klintmalm; William E Fitzsimmons; Carol Uleman Journal: Liver Transpl Date: 2004-10 Impact factor: 5.799
Authors: Marina Berenguer; Martín Prieto; Fernando San Juan; José M Rayón; Fernando Martinez; Domingo Carrasco; Angel Moya; Francisco Orbis; José Mir; Joaquín Berenguer Journal: Hepatology Date: 2002-07 Impact factor: 17.425
Authors: Marina Berenguer; Victoria Aguilera; Martín Prieto; Fernando San Juan; José M Rayón; Salvador Benlloch; Joaquín Berenguer Journal: Liver Transpl Date: 2006-05 Impact factor: 5.799
Authors: Abdulkareem M Albekairy; Wesam S Abdel-Razaq; Abdulmalik M Alkatheri; Tariq M Al Debasi; Nouf E Al Otaibi; Amjad M Qandil Journal: Int J Health Sci (Qassim) Date: 2018 Jul-Aug
Authors: Mostafa K El Awady; Noha G Bader El Din; Mahmoud Abdel Aziz Riad; Moataza H Omran; Tawfeek H Abdelhafez; Tamer Mahmoud Elbaz; Shereen Shoukry Hunter; Reham M Dawood; Ashraf O Abdel Aziz Journal: Dis Markers Date: 2014-02-18 Impact factor: 3.434